Type 2 diabetes drug Ozempic and weight loss medication Wegovy cost hundreds of dollars more in the U.S. than similar nations, and Novo Nordisk is profiting so much that Denmark’s economy is shifting.
Read the full post on Becker's Hospital Review - Healthcare News
